All In Biotech

Drug Trial Radar · NCT00223691

Treatment of Orthostatic Hypotension in Autonomic Failure

Evaluation and Treatment of Autonomic Failure.

Last checked: Nov 19, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 389 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

389

Actual

Start

Mar 2002

Primary completion

Jan 2017

Study completion Jan 2017

Sponsor

Lead sponsor
Vanderbilt UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.

Conditions

  • Autonomic Failure
  • Orthostatic Hypotension

Interventions

  • AtomoxetineDrug

    10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.

  • AcarboseDrug

    25-100 mg, PO. Single dose.

  • Pyridostigmine BromideDrug

    30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.

  • YohimbineDrug

    2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.

  • Midodrine HClDrug

    2.5, 5.0, 7.5, 10 mg PO. Single dose

  • placeboDrug

    PO.Single dose.

  • ModafinilDrug

    50-400 mg PO. Single dose

  • OctreotideDrug

    5-50 µg, S.C. Single dose.

  • water intakeOther

    Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.

  • Diphenhydramine HydrochlorideDrug

    12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine

  • Ranitidine HCLDrug

    150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.

  • TranylcypromineDrug

    5 - 40 mg PO. Single dose

  • Ergotamine/ CaffeineDrug

    Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose

  • CelecoxibDrug

    50-200 mg PO. Single dose

  • PseudoephedrineDrug

    15, 30 or 60 mg, PO. Single dose.

  • MethylphenidateDrug

    5 or 10 mg PO. Single dose.

  • IndomethacinDrug

    25, 50 or 75 mg, PO. Singe dose.

  • IbuprofenDrug

    300, 600 or 900 mg, PO. Single dose.

  • Oxymetazoline 0.05% nasal solutionDrug

    1-2 sprays/ nostril. Single dose.

  • BovrilDietary supplement

    6-10 g, PO. Single dose.

  • AcetazolamideDrug

    125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine

  • Rivastigmine tartrateDrug

    1.5-6 mg PO. Single dose.

  • Carbidopa/levodopaDrug

    10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg

  • Inflatable abdominal binderDevice

    External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).

  • inflatable abdominal binder (sham)Device

    External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Increase in seated systolic blood pressure 1-hr post drug compared to baseline.Time frame: 1.5-4 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.